EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today launched the EVERSANA AI Accelerator, a dedicated center of excellence (COE) focused on the transformation of life sciences commercialization through the power of AI. Under the leadership of Faruk Capan, EVERSANA’s Chief Innovation Officer, the EVERSANA AI Accelerator will reimagine every stage of life sciences commercialization through cutting-edge AI research, transformation services and solutions development.
“Faruk and team have created the space where AI innovation in our complex sector is born. Not only is it transforming every facet of our operation, but it is also creating a healthier world,” said Jim Lang, Chief Executive Officer of EVERSANA. “Frankly, patients have waited far too long to reap the benefits of what’s possible when pharma commercialization is propelled by AI.”
The McKinsey Global Institute (MGI) has estimated that generative AI is expected to produce $60 billion to $110 billion in annual value across the pharmaceutical value chain, with $18 billion to $30 billion in commercialization alone.
Core components of the EVERSANA AI Accelerator include:
- Dedicated AI and Commercialization Expertise: AI innovators working with life sciences leaders to reimagine global drug pricing, promotion, access, reimbursement, adherence, and product delivery challenges.
- Formidable Technology Partnerships: Collaborations with leading technology companies such as Amazon Web Services, Google, Salesforce, Veeva and Modus Create.
- Forward-Thinking Pharmaceutical Companies: Representation from pharmaceutical and medical device companies and start-ups deploying or piloting new AI platforms and toolsets.
- Breakthrough Technology Deployments: Development and deployment of proprietary and/or third-party technologies into the AI-activated EVERSANA ORCHESTRATE™ Operating System.
Recent deployments from the EVERSANA AI Accelerator include EVERSANA ORCHESTRATE MLR, an AI-powered Medical, Legal & Regulatory platform that was recently awarded an Emerald Pinnacle Technology Award. The AI Accelerator’s R&D pipeline is currently beta-testing advancements in pharmaceutical marketing, patient hub services and broader end-to-end commercialization operations.
“Innovation isn’t new to EVERSANA. From our COMPLETE Commercialization model to the use of agentic KOL influencers, evolution is in our DNA. Today, we give that spirit of transformation a home in our global enterprise,” added Lang. “We invite our clients and partners to collaborate and build what’s next.”
For more information about the EVERSANA AI Accelerator, to request technology demonstration, or to initiate a research and development collaboration, please visit eversana.ai.